Search results
Showing 61 to 75 of 103 results for rituximab
Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma (TA677)
Evidence-based recommendations on brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma in adults who have previously had a Bruton’s tyrosine kinase (BTK) inhibitor.
Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia (TA663)
Evidence-based recommendations on venetoclax (Venclyxto) with obinutuzumab for untreated chronic lymphocytic leukaemia in adults.
Evidence-based recommendations on caplacizumab (Cablivi) with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura in adults, and in young people aged 12 years and over who weigh at least 40 kg.
Evidence-based recommendations on adalimumab, etanercept, infliximab and abatacept for adults with moderate rheumatoid arthritis who have tried conventional DMARDs but they have not worked.
This guideline covers assessing and managing chronic hepatitis B in children, young people and adults. It aims to improve care for people with hepatitis B by specifying which tests and treatments to use for people of different ages and with different disease severities.
Prevention of recurrence of C3 glomerulopathy post-transplant: eculizumab (ESUOM44)
Summary of the evidence on eculizumab to prevent the recurrence of C3 glomerulopathy post-transplant to inform local NHS planning and decision-making
In development [GID-TA11495] Expected publication date: TBC
Evidence-based recommendations on belumosudil (Rezurock) for chronic graft-versus-host disease in people 12 years and over after 2 or more systemic treatments.
Rozanolixizumab for treating antibody-positive generalised myasthenia gravis [ID5092]
In development [GID-TA10994] Expected publication date: TBC
Eltrombopag for treating chronic immune thrombocytopenia (TA293)
Evidence-based recommendations on eltrombopag (Revolade) for treating chronic immune thrombocytopenia in adults.
Evidence-based recommendations on axicabtagene ciloleucel (Yescarta) for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy.
C3 glomerulopathy in the native kidney: eculizumab (ESUOM49)
Summary of the evidence on eculizumab for treating C3 glomerulopathy in the native kidney inform local NHS planning and decision-making
Avatrombopag for treating primary chronic immune thrombocytopenia (TA853)
Evidence-based recommendations on avatrombopag (Doptelet) for treating primary chronic immune thrombocytopenia in adults.
November 2017 TA193 Leukaemia (chronic lymphocytic, relapsed) - rituximab 25 May 2010 TA251 Leukaemia (chronic myeloid) - dastatinib,...
Bendamustine for the first-line treatment of chronic lymphocytic leukaemia (TA216)
Evidence-based recommendations on bendamustine for treating chronic lymphocytic leukaemia in adults.